AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04663854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trehalose
Description: Trehalose is a natural disaccharide sugar found extensively among miscellaneous organisms including bacteria, plants, insects, yeast, fungi, and invertebrates. By preventing protein denaturation, it plays various protective roles against stress conditions such as heat, freeze, oxidation, desiccation and dehydration. Owing to this capacity, trehalose is an FDA-approved pharmaceutical excipient that is used as a stabilizer in numerous medicines including parenteral products. In this study, all injections will be conducted by a trained nurse in the presence of a specialist physician at a duration of 45-90 minutes.
Study NCT03423147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate cloth
Description: applied to their abdomen
Study NCT03423147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% chlorhexidine gluconate cloth
Description: applied to their abdomen
Study NCT03423147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% Chlorhexidine gluconate vaginal scrub
Description: applied as a vaginal cleanse in the operating room prior to cesarean section
Study NCT03879551 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation
Description: By defining intensity of 80% of the resting Motor Threshold detected from motor area for Rt Abductor digiti minimi (ADM), we will apply repetitive Transcranial Magnetic Stimulation (rTMS) using 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Magnetic Stimulator with high frequency (25Hz), Stimuli will be delivered for total 2000 pulse (divided on 50 trains with 40 pulses per train with inter-train interval 30 seconds) for each hemisphere (coil placed tangential over the optimal position of hand motor area detected for Real group and the same coil placed perpendicular with hand of coil pointing upward over occipital cortex for Sham group). Sessions will be consecutive for ten days period with repetition of consecutive 5 sessions as boosting doses on 5 days period over the follow up visits every month for the next 3 months.
Study NCT03879551 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation
Description: By defining intensity of 80% of the resting Motor Threshold detected from motor area for Rt Abductor digiti minimi (ADM), we will apply repetitive Transcranial Magnetic Stimulation (rTMS) using 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Magnetic Stimulator with high frequency (25Hz), Stimuli will be delivered for total 2000 pulse (divided on 50 trains with 40 pulses per train with inter-train interval 30 seconds) for each hemisphere (coil placed tangential over the optimal position of hand motor area detected for Real group and the same coil placed perpendicular with hand of coil pointing upward over occipital cortex for Sham group). Sessions will be consecutive for ten days period with repetition of consecutive 5 sessions as boosting doses on 5 days period over the follow up visits every month for the next 3 months.
Study NCT03236571 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rehabilitation program
Description: The rehabilitation program will consist of a Personalized Training Program and a muscle building program.
Study NCT04933864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue and Photodynamic Therapy
Description: Treatment group. Methylene blue (SamaraMedProm, Russia, Registration number: MP-001834, 13.09.2012) 1 mg/kg concentration orally one time were added to the current therapy of the participant (e.g., azithromycin, hydroxychloroquine, aminodihydrophthalazinedione sodium, levofloxacin, etc.), if any, and irradiation of the participant's chest was performed by 650 nm laser source (UFPh-675-01-BIOSPEC, BIOSPEC, Russia, Registration number: 2009/04648, 26.03.2009) with 18 J/cm\^2 energy dose.~For critically ill participants: Inhalation by 0.2 mg methylene blue (SamaraMedProm, Russia, Registration number: MP-001834, 13.09.2012) 10 ml water solution and irradiation of pharynx and nasal cavity by 650 nm laser source (UFPh-675-01-BIOSPEC, BIOSPEC, Russia, Registration number: 2009/04648, 26.03.2009) with 36 J/cm\^2 energy dose were performed.
Study NCT00840034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: Starting dose is 6 milligrams (mg), then titrate up to 9 mg, 12 mg, or 18 mg (3 tablets) administered orally (PO), once daily (QD) for up to 10 weeks followed by a 2 week taper.
Study NCT00840034 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 tablets PO QD for up to 12 weeks
Study NCT03605472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical ultrasound
Description: cervical ultrasound will be realized by a endocinologist trained in the cervical ultrasound
Study NCT03411902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate Sodium 150 MG
Description: Subjects randomized to the Risedronate group will take a 150 mg capsule of oral Risedronate once every 4 weeks for 24 weeks (6 doses), beginning 1 week prior to surgery and dispensed in blinded capsules from the WFSM research pharmacy.
Study NCT03411902 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to the placebo group will receive 150 mg placebo capsule once every 4 weeks for 24 weeks (6 doses), beginning 1 week prior to surgery and dispensed in blinded capsules from the WFSM research pharmacy.
Study NCT03909698 — intervention group
Intervention type: OTHER
Intervention: Blood and urine sampling
Description: During a period of maximum 6 days blood is sampled at different time points and urine is collected during documented time intervals.
Study NCT01072747 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bovine heparin
Description: 5.000UI/mL bottle with 5mL
Study NCT01072747 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Porcine heparin
Description: 5000 USP Heparin Units / mL vial with 10 mL vial
Study NCT04099537 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training
Description: Participants are trained to approach or avoid stimuli of skin using a joystick. Participants are to pull or push the joystick toward or away when skin stimuli are present. Thus, behaviorally, there may be an increase, decrease, or no change in approach tendencies towards skin.
Study NCT04099537 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Computerized cognitive training
Description: Participants are trained to approach or avoid stimuli of skin using a joystick. Participants are to pull or push the joystick toward or away when skin stimuli are present. Thus, behaviorally, there may be an increase, decrease, or no change in approach tendencies towards skin.
Study NCT02336009 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: total wrist arthroplasty, Trimed
Description: A new total wrist arthroplasty design. A pilot study.
Study NCT00280696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam 250 mg
Description: * Active Substance: Levetiracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 250 mg~* Route of Administration: Oral Use
Study NCT00450515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinflunine
Study NCT00613613 — intervention group
Intervention type: DRUG
Intervention: fenofibrate
Description: Fenofibrate 145mg tablets once daily for 4 weeks
Study NCT00280696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam 500 mg
Description: * Active Substance: Levetiracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 500 mg~* Route of Administration: Oral Use
Study NCT00280696 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Active Substance: Placebo~* Pharmaceutical Form: Film-coated tablet~* Concentration: 250 mg and 500 mg~* Route of Administration: Oral Use
Study NCT02502695 — intervention group
Intervention type: OTHER
Intervention: VATS-associated best practices
Study NCT00960973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menatetrenone
Description: Menatetrenone 30 mg, 3 times a day for 4 weeks
Study NCT00960973 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01440582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Induction Therapy (Part A, 21-day cycles): 10 mg by mouth on Days 1, 3, 5, 8, 10, and 12 for 2 weeks with 1 week of rest at the end of each cycle.~Induction Therapy (Part B, 28-day cycles): 10 mg by mouth on Days 1, 3, 5, 15, 17, and 19 of every cycle.~Maintenance dose (Part A, 28-day cycles): Maximum tolerated dose (MTD) from Induction phase on Days 1, 3, 5, 8, 10, and 12 of each cycle.~Maintenance dose (Part B, 28-day cycles): Maximum tolerated dose (MTD) from Induction phase on Days 1, 3, 5, 15, 17, 19 of each cycle.
Study NCT01440582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Induction Therapy (Part A, 21-day cycles): 1.3 mg/m\^2 by vein daily on days 1, 4, 8 and 11 of Cycles 1 - 8.~Induction Therapy (Part B, 28-day cycles): 1.3 mg/m\^2 by vein daily on days 1, 8 and 15 of Cycles 1 - 8.
Study NCT01440582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Induction Therapy (Part A, 21-day cycles): 25 mg by mouth daily on days 1-14 of every cycle.~Induction Therapy (Part B, 28-day cycles): 25 mg by mouth daily on days 1-21 of every cycle.~Maintenance dose (Parts A and B, 28-day cycles): Last tolerated dose from Induction Phase on Days 1 - 21 of each cycle.
Study NCT01440582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Induction Therapy (Part A, 21-day cycles): 20 mg by mouth daily on Days 1, 2, 4, 5, 8, 9, 11 and 12 of Cycles 1 - 8.~Induction Therapy (Part B, 28-day cycles): 20 mg by mouth daily on Days 1, 2, 8, 9, 15 and 16 of Cycles 1-8.~Maintenance dose (Parts A and B, 28-day cycles): Last tolerated dose from Induction Phase on Days 1, 8, 15, 21 of each cycle.
Study NCT01440582 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom Questionnaire
Description: Completed on day 1 of each cycle.
Study NCT04865692 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Physical Therapy
Description: knee isometrics, resisted knee extension with chalanging weight 2 sets of 10 Reps with 5 sec hold
Study NCT03542162 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Healaflow
Description: For the RRD patients, after 27G PPV, air-liquid exchange and endolaser photocoagulation around the tear(s), Healaflow is going to be fully covered on the surface of all retinal tears using 27G needle, the amount of Healaflow injection was determined according to the size of tears.
Study NCT01151423 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Caplacizumab
Description: * Subjects received a first intravenous (i.v.) bolus of 10 mg (filled at 5 mg/mL) caplacizumab via push injection within 6 hours to 15 minutes prior to the first PE on study. The first PE on study could either be the very first PE session for the current episode of aTTP (if the subject was randomized prior to the initiation of PE) or the second PE session (if the subject was randomized after a single PE session).~* The first PE on study was followed by subcutaneous (s.c.) administration of 10 mg study drug within 30 minutes after the end of the PE procedure.~* All subsequent study drug administrations were daily s.c. injections within 30 minutes after the end of the PE procedure (if applicable) or within 24 hours of the previous dose.~* Subjects received caplacizumab up to 30 days after the last PE session.
Study NCT01151423 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Subjects received a first i.v. bolus of placebo via push injection within 6 hours to 15 minutes prior to the first PE on study. The first PE on study could either be the very first PE session for the current episode of aTTP (if the subject was randomized prior to the initiation of PE) or the second PE session (if the subject was randomized after a single PE session).~* The first PE on study was followed by s.c. administration of placebo within 30 minutes after the end of the PE procedure.~* All subsequent study drug administrations were daily s.c. injections within 30 minutes after the end of the PE procedure (if applicable) or within 24 hours of the previous dose.~* Subjects received placebo up to 30 days after the last PE session.
Study NCT03635736 — intervention group
Intervention type: OTHER
Intervention: multiple-spectral-sonography as acustocerebrography (ACG)
Description: After inclusion three times at day measurements with ACG for each 45 minutes; a (non-invasive) sonography. The measurements will be stopped after final evaluation of the neurological status using common methods like magnetic resonance tomography, transcranial doppler sonography, electroencephalography and other methods.
Study NCT01103232 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Electrical muscle stimulation (EMS) of the right wrist flexor muscles was applied. EMS was applied for 20 minutes. Maximum current intensity tolerated was used so as to stimulate the highest possible number of motor unit. The stimulation intensity increased every five minutes during a session. Electrical stimulation was applied for thirty sessions (one session a day, five days a week for six weeks.)
Study NCT01831414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water immersion at cervical level
Description: balneotherapy session of spinal cord patients with a Water immersion at cervical level
Study NCT01831414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water immersion at xyphoid level
Description: balneotherapy session of spinal cord patients with a Water immersion at xyphoid level
Study NCT04547426 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wine with or without alcohol and snuff with or without nicotine
Description: Two by two factorial of wine and snuff with meals
Study NCT04547426 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Wine with or without alcohol and snuff with or without nicotine
Description: Two by two factorial of wine and snuff with meals
Study NCT00127413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy - Pain
Description: Pain treatment
Study NCT00127413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy-Integrated
Description: Integrated treatment
Study NCT00127413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy - PTSD
Description: Cognitive processing therapy
Study NCT00127413 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treat as Usual
Description: Treatment as usual
Study NCT01049061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORAb-003
Description: MORAb-003 is intravenously administered to patients with solid tumor once a week for 4 weeks as 1 cycle in order to investigate dose-limiting toxicity and estimate maximum tolerated dose
Study NCT02934516 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cesarean section
Description: Abdominal disimpaction with lower uterine segment support: the edge of the lower uterine segment is grasped by 3-4 modified Allies forceps (with broader jaws) applied along the lower edge of the incision until it is completely supported. These forceps are handled by the assistant, and gentle traction is applied upward, perpendicular to the uterine surface and away from the fetal head without excessive force. Accordingly, the hand of the surgeon could be inserted into the uterine cavity, and adequate space for manipulations is available without applying pressure on the lower segment. The fetal head is eventually grasped and delivered.~Classic push method: delivering the head with assistance by pushing the fetal head vaginally
Study NCT02934516 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cesarean section
Description: Abdominal disimpaction with lower uterine segment support: the edge of the lower uterine segment is grasped by 3-4 modified Allies forceps (with broader jaws) applied along the lower edge of the incision until it is completely supported. These forceps are handled by the assistant, and gentle traction is applied upward, perpendicular to the uterine surface and away from the fetal head without excessive force. Accordingly, the hand of the surgeon could be inserted into the uterine cavity, and adequate space for manipulations is available without applying pressure on the lower segment. The fetal head is eventually grasped and delivered.~Classic push method: delivering the head with assistance by pushing the fetal head vaginally
Study NCT04140890 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habit Formation
Description: Treatment sessions consist of 12 weekly health coaching sessions at participants' home. During the intervention period, an occupational therapist will help the participant to commit to developing new simple habits (dietary habits or physical activity habits) in each 60-minute session.
Study NCT04140890 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Education
Description: In the education group, participants will receive newsletters containing general healthy aging materials over 12 weeks. A trained research assistant will call participants to verify receipt of the newsletter, and answer their questions about the materials. Each phone call will last \~15 minutes.
Study NCT00618462 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: CBT will include weekly 50-minute sessions for 8 weeks. The sessions will focus on learning skills to cope with urges to gamble and developing alternatives to gambling.
Study NCT00618462 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management (CM)
Description: CM will provide incentive, such as a gift certificate to a store or restaurant, for completing activities not related to gambling. Participants and their therapists will decide upon two potential alternative activities to gambling during each therapy session.
Study NCT00618462 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation therapy
Description: Psychoeducation therapy will include weekly 50-minute therapy sessions for 8 weeks. The sessions will focus on education about gambling and related problems.
Study NCT00618462 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case management
Description: Case management will assist participants in obtaining additional services from the community as needed.
Study NCT00618462 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gamblers Anonymous (GA)
Description: All participants will be referred to GA, a support group of people who are recovering from gambling addiction, and will be encouraged to attend meetings.
Study NCT00822315 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz
Description: tenofovir 245 mg / lamivudine 300 mg / efavirenz 600 mg
Study NCT00822315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir
Description: tenofovir 245 mg / lamivudine 300 mg / raltegravir 400 mg
Study NCT00822315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir
Description: tenofovir 245 mg / lamivudine 300 mg / raltegravir 800 mg
Study NCT01778062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol 150µg once daily oral inhalation
Study NCT01778062 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Placebo once daily oral inhalation
Study NCT01715623 — intervention group
Intervention type: BIOLOGICAL
Intervention: a blood sample
Description: Dosage of Ig
Study NCT01054196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: daily dose dependent on dose-escalation schedule
Study NCT01054196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: 100 mg/m2 given Days -2 and -1
Study NCT00003458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Children with a brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
Study NCT01474837 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention: Exercise and motivational interviewing
Description: 12 sessions of exercise with MI
Study NCT02834572 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: All About Me
Description: Assessment and algorithm to determine recommended HIV testing approach
Study NCT02834572 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: HIV testing information
Study NCT00050089 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP
Description: Continuation or interruption of ART treatment
Study NCT00050089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard ART vs Mega ART
Description: Standard therapy vs Intensified therapy
Study NCT01103232 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: Conventional mode of transcutaneous electrical nerve stimulation (TENS) was applied for the control subjects. TENS was applied for 20 minutes. The stimulus intensity was adjusted as the lowest current at which the subject felt only a slight tickling of the impulses. A visible, and palpable muscle contraction was not provided during TENS stimulation. The stimulus intensity was not changed during the first session. Subsequently, TENS was applied at same intensity in all sessions. TENS was applied for thirty sessions (one session a day, five days a week for six weeks).
Study NCT02145169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Nitrous Oxide
Description: Patients undergoing procedural sedation with Ketamine will receive inhaled Nitrous Oxide